CompletedNot Applicable

Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.

Canada30 participantsStarted 2016-05-15

Plain-language summary

To evaluate a Novel infusion protocol in MS patients treated with Alemtuzumab

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patient s treated with Alemtuzumab as per canadian label - Exclusion Criteria: Contraindication to Alemtuzumab \-

Number and type of adverse events in Novel versus standard infusion protocol

Timeframe: 2016-2020

NCT IDNCT04633967

SponsorMaritime Neurology

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2020-12-30